332 Antidepressant (AD) use in ovarian cancer patients (OC) in the past 26 years at the american university of beirut medical center (AUBMC). (18th September 2019)
- Record Type:
- Journal Article
- Title:
- 332 Antidepressant (AD) use in ovarian cancer patients (OC) in the past 26 years at the american university of beirut medical center (AUBMC). (18th September 2019)
- Main Title:
- 332 Antidepressant (AD) use in ovarian cancer patients (OC) in the past 26 years at the american university of beirut medical center (AUBMC)
- Authors:
- Seoud, M
Abdallah, R
Dagher, C
Jaafar, I
Shamseddine, W
Jaafar, N - Abstract:
- Abstract : Objectives: To assess the prevalence of antidepressant (AD) use and the factors affecting it in OC patients at AUBMC between the years 1992–2018. Methods: A Retrospective review of patients with OC stages I-IV cared for in AUBMC between 1992–2018, with focus on antidepressant use and the factors affecting it. Results: A total number of 330 subjects were enrolled in this study. Prevalence of antidepressant use is 11.8%. Anxiolytics were prescribed in 42.8% of cases. 20.3% of patients on anxiolytics were on AD as well (P-value<0.001). AD use was significantly higher among the advanced ovarian cancer patients (IIIC:37%, IV=39%) versus early stages (IA-IIIB=25%). 23.4% of diabetic patients versus 9.8% of non-diabetic patients were on AD (P-value=0.021), 26% of smokers versus 9% of non smokers (p=0.006), 28% of Dyslipidemics versus 8.7% of non-dyslipidemics (P-value<0.001), and 22.9% employed patients versus 11.3% of unemployed ones (Pvalue=0.057) were on AD. Antidepressant prescription was found to be significantly correlating with having dyslipidemia (OD=7.3, P-value<0.001), being on anxiolytics (OD=6.9, P-value<0.001), having an advanced FIGO stage(OD=3.7, P-value<0.001), and being employed (OD=3.66, P-value=0.02) (table 1 ). Conclusions: Depression among ovarian cancer patients is underestimated or not properly screened and treated. Advanced FIGO stage, being employed, dysplipidemic and anxiolytic are significant predictors for AD use.
- Is Part Of:
- International journal of gynecological cancer. Volume 29(2019)Supplement 3
- Journal:
- International journal of gynecological cancer
- Issue:
- Volume 29(2019)Supplement 3
- Issue Display:
- Volume 29, Issue 3 (2019)
- Year:
- 2019
- Volume:
- 29
- Issue:
- 3
- Issue Sort Value:
- 2019-0029-0003-0000
- Page Start:
- A137
- Page End:
- A138
- Publication Date:
- 2019-09-18
- Subjects:
- Generative organs, Female -- Cancer -- Periodicals
616.99465 - Journal URLs:
- http://journals.lww.com/ijgc/pages/default.aspx ↗
http://www3.interscience.wiley.com/journal/118544021/toc ↗
https://ijgc.bmj.com/ ↗
http://journals.lww.com ↗ - DOI:
- 10.1136/ijgc-2019-IGCS.332 ↗
- Languages:
- English
- ISSNs:
- 1048-891X
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - 4542.273500
British Library DSC - BLDSS-3PM
British Library HMNTS - ELD Digital store - Ingest File:
- 19724.xml